In our technology platforms, we use a variety of different payloads to research, manufacture and clinically develop highly effective ADCs for the treatment of a variety of malignant hematological and solid tumors. ADCs combine the high affinity and specificity of antibodies with the potency of small toxic molecules to fight cancer.

With our unique expertise in the active ingredient Amanitin from the green death cap mushroom, we have developed a patented and proprietary ATAC technology. The toxin's unique mode of action offers the opportunity to break through drug resistance and eliminate even quiescent tumor cells, which could lead to significant advances in cancer therapy – even for patients who no longer respond to any other treatment.